Suzumori K, Yasui Y, Yagami Y, Kimura K
Gan To Kagaku Ryoho. 1987 Jul;14(7):2341-6.
The antitumor effects of human recombinant TNF (PAC-4D) were examined on three human gynecological carcinomas transplanted into CD-1 nude mice (uterine cervical carcinoma: UZ-1-N; ovarian carcinoma: OCl-1-N and OS-4-N). PAC-4D was administered intratumorally at a dose of 1,000 U, 3,000 U or 10,000 U/head from day 0 to day 4. Tumor size, body weight and peripheral WBC were measured on days 0, 4, 8, 12 and 16 and histological studies were made on day 6. The results were as follows: With UZ-1-N, intratumoral administration of PAC-4D at doses of 3,000 U and 10,000 U/head caused a marked inhibition of the tumor growth. Similarly, antitumor activity of PAC-4D against OCl-1-N was remarkable at a dose of 10,000 U/head. The administration of PAC-4D at doses of 3,000 U and 10,000 U/head was not effective against OS-4-N. The histological changes of grade II A-B by Ohboshi-Shimosato criteria of response were observed in the tumor of the effective groups against PAC-4D. There were no influences on the body weight and WBC after administration of PAC-4D. Although tumor cells possessed different sensitivities to PAC-4D, PAC-4D is strongly recommended for the treatment of gynecological malignancies.
研究了人重组肿瘤坏死因子(PAC-4D)对移植到CD-1裸鼠体内的三种人类妇科癌(子宫颈癌:UZ-1-N;卵巢癌:OCl-1-N和OS-4-N)的抗肿瘤作用。从第0天至第4天,以1000 U、3000 U或10000 U/只的剂量对肿瘤内注射PAC-4D。在第0、4、8、12和16天测量肿瘤大小、体重和外周血白细胞,并在第6天进行组织学研究。结果如下:对于UZ-1-N,以3000 U和10000 U/只的剂量对肿瘤内注射PAC-4D可显著抑制肿瘤生长。同样,PAC-4D对OCl-1-N的抗肿瘤活性在剂量为10000 U/只时显著。以3000 U和10000 U/只的剂量对肿瘤内注射PAC-4D对OS-4-N无效。在对PAC-4D有效的组的肿瘤中观察到符合Ohboshi-Shimosato反应标准的II A-B级组织学变化。注射PAC-4D后对体重和白细胞没有影响。尽管肿瘤细胞对PAC-4D具有不同的敏感性,但强烈推荐PAC-4D用于治疗妇科恶性肿瘤。